Circulating nef induces dyslipidemia in simian immunodeficiency virus-infected macaques by suppressing cholesterol efflux

Journal of Infectious Diseases

Volumn 202, Issue 4, 2010, Pages 614-623

  Asztalos, Bela F ^a   Mujawar, Zahedi ^c   Morrow, Matthew P ^e   Grant, Angela ^e   Pushkarsky, Tatiana ^e   Wanke, Christine ^b   Shannon, Richard ^f   Geyer, Matthias ^g   Kirchhoff, Frank ^h   Sviridov, Dmitri ⁱ   Fitzgerald, Michael L ^c   Bukrinsky, Michael ^e   Mansfield, Keith G ^d  

^a U S DEPARTMENT OF AGRICULTURE   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g MAX PLANCK INSTITUTE OF MOLECULAR PHYSIOLOGY   (Germany)

^h UNIVERSITY OF ULM   (Germany)

ⁱ BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER A1; HIGH DENSITY LIPOPROTEIN; NEF PROTEIN;

ARTICLE; ATHEROGENIC DIET; BLOOD SAMPLING; CELL LYSATE; CHOLESTEROL TRANSPORT; DISEASE EXACERBATION; DOWN REGULATION; DYSLIPIDEMIA; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; INOCULATION; LIVER; LIVER CELL; MACACA; MACROPHAGE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SIMIAN IMMUNODEFICIENCY VIRUS; VIROTHERAPY; VIRUS INFECTION; WESTERN BLOTTING;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; CELLS, CULTURED; CHOLESTEROL; DYSLIPIDEMIAS; HEPATOCYTES; LIVER; MACACA MULATTA; MACROPHAGES; NEF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 77954743165     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/654817     Document Type: Article

References (50)

1. Friis-Moller N, Weber R, Reiss P, et al. Cardiovascular disease risk factors in HIV patients-association with antiretroviral therapy: results from the DAD study. AIDS 2003; 17(8):1179-1193.
2. Boccara F. Cardiovascular complications and atherosclerotic manifestations in the HIV-infected population: type, incidence and associated risk factors. AIDS 2008; 22(suppl 3):S19-S26.
3. Riddler SA, Smit E, Cole SR, et al. Impact of HIV infection andHAART on serum lipids in men. JAMA 2003; 289(22):2978-2982.
4. El Sadr WM, Mullin CM, Carr A, et al. Effects of HIV disease on lipid, glucose and insulin levels: results from a large antiretroviral-naive cohort. HIV Med 2005; 6(2):114-121.
5. Rose H, Hoy J, Woolley I, et al. HIV infection and high density lipoprotein metabolism. Atherosclerosis 2008; 199(1):79-86.
6. Oliviero U, Bonadies G, Apuzzi V, et al. Human immunodeficiency virus per se exerts atherogenic effects. Atherosclerosis 2009; 204(2):586-589.
7. Rose H, Woolley I, Hoy J, et al. HIV infection and high-density lipoprotein: the effect of the disease vs the effect of treatment. Metabolism 2006; 55(1):90-95.
8. Mujawar Z, Rose H, Morrow MP, et al. Human immunodeficiency virus impairs reverse cholesterol transport from macrophages. PLoS Biol 2006; 4(11):e365.
9. Asztalos BF, de la Llera-Moya M, Dallal GE, Horvath KV, Schaefer EJ, Rothblat GH. Differential effects of HDL subpopulations on cellular ABCA1-and SR-BI-mediated cholesterol efflux. J Lipid Res 2005; 46(10):2246-2253.
10. Bergersen BM. Cardiovascular risk in patients with HIV Infection: impact of antiretroviral therapy. Drugs 2006; 66(15):1971-1987.
11. Chong KS, Nicolosi RJ, Rodger RF, et al. Effect of dietary fat saturation on plasma lipoproteins and high density lipoprotein metabolism of the rhesus monkey. J Clin Invest 1987; 79(3):675-683.
12. Khosla P, Hayes KC. Dietary fat saturation in rhesus monkeys affects LDL concentrations by modulating the independent production of LDL apolipoprotein B. Biochim Biophys Acta 1991; 1083(1):46-56.
13. Mansfield KG, Carville A, Wachtman L, et al. A diet high in saturated fat and cholesterol accelerates simian immunodeficiency virus disease progression. J Infect Dis 2007; 196(8):1202-1210.
14. Yearley JH, Pearson C, Carville A, Shannon RP, Mansfield KG. SIVassociated myocarditis: viral and cellular correlates of inflammation severity. AIDS Res Hum Retroviruses 2006; 22(6):529-540.
15. Asztalos B, Zhang W, Roheim PS, Wong L. Role of free apolipoprotein A-I in cholesterol efflux: formation of pre-alpha-migrating high-density lipoprotein particles. Arterioscler Thromb Vasc Biol 1997; 17(9):1630-1636.
16. Schmidtmayerova H, Nuovo GJ, Bukrinsky M. Cell proliferation is not required for productive HIV-1 infection of macrophages. Virology 1997; 232(2):379-384.
17. Knowles BB, Howe CC, Aden DP. Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen. Science 1980; 209(4455):497-499.
18. Wachtman LM, Gualtieri L, Wanke C, Shannon R, Mansfield KG. Viral and host correlates of serum resistin in simian AIDS. AIDS Res Hum Retroviruses 2008; 24(1):34-42.
19. Lamon-Fava S, Herrington DM, Reboussin DM, et al. Plasma levels of HDL subpopulations and remnant lipoproteins predict the extent of angiographically-defined coronary artery disease in postmenopausal women. Arterioscler Thromb Vasc Biol 2008; 28(3):575-579.
20. Asztalos BF, Collins D, Cupples LA, et al. Value of high-density lipoprotein (HDL) subpopulations in predicting recurrent cardiovascular events in the Veterans Affairs HDL Intervention Trial. Arterioscler Thromb Vasc Biol 2005; 25(10):2185-2191.
21. Yearley JH, Xia D, Pearson CB, Carville A, Shannon RP, Mansfield KG. Interleukin-18 predicts atherosclerosis progression in SIV-infected and uninfected rhesus monkeys (Macaca mulatta) on a high-fat/high-cholesterol diet. Lab Invest 2009; 89(6):657-667.
22. Asztalos BF, Schaefer EJ, Horvath KV, et al. Role of LCAT in HDL remodeling: investigation of LCAT deficiency states. J Lipid Res 2007; 48(3):592-599.
23. Denis M, Haidar B, Marcil M, Bouvier M, Krimbou L, Genest J Jr. Molecular and cellular physiology of apolipoprotein A-I lipidation by the ATP-binding cassette transporter A1 (ABCA1). J Biol Chem 2004; 279(9):7384-7394.
24. Singaraja RR, Stahmer B, Brundert M, et al. Hepatic ATP-binding cassette transporter A1 is a key molecule in high-density lipoprotein cholesteryl ester metabolism in mice. Arterioscler Thromb Vasc Biol 2006; 26(8):1821-1827.
25. Wellington CL, Walker EK, Suarez A, et al. ABCA1 mRNA and protein distribution patterns predict multiple different roles and levels of regulation. Lab Invest 2002; 82(3):273-283.
26. Fujii Y, Otake K, Tashiro M, Adachi A. Soluble Nef antigen of HIV-1 is cytotoxic for human CD4+ T cells. FEBS Lett 1996; 393(1):93-96.
27. Qiao X, He B, Chiu A, Knowles DM, Chadburn A, Cerutti A. Human immunodeficiency virus 1 Nef suppresses CD40-dependent immunoglobulin class switching in bystander B cells. Nat Immunol 2006; 7(3):302-310.
28. Campbell TD, Khan M, Huang MB, Bond VC, Powell MD. HIV-1 Nef protein is secreted into vesicles that can fuse with target cells and virions. Ethn Dis 2008; 18(2 Suppl 2):S2-S9.
29. Gomez-Icazbalceta G, Huerta L, Soto-Ramirez LE, Larralde C. Extracellular HIV-1 Nef protein modulates lytic activity and proliferation of human CD8+ T lymphocytes. Cell Immunol 2007; 250(1-2):85-90.
30. Neufeld EB, Remaley AT, Demosky SJ, et al. Cellular localization and trafficking of the human ABCA1 transporter. J Biol Chem 2001; 276(29): 27584-27590.
31. Kirchhoff F, Schindler M, Bailer N, et al. Nef proteins from simian immunodeficiency virus-infected chimpanzees interact with p21-activated kinase 2 and modulate cell surface expression of various human receptors. J Virol 2004; 78(13):6864-6874.
32. Luo T, Garcia JV. Regulation of Nef function. Res Virol 1997; 148(1): 64-68.
33. Jin YJ, Cai CY, Zhang X, Burakoff SJ. Lysine 144, a ubiquitin attachment site in HIV-1 Nef, is required for Nef-mediated CD4 down-regulation. J Immunol 2008; 180(12):7878-7886.
34. Greenberg ME, Bronson S, Lock M, Neumann M, Pavlakis GN, Skowronski J. Co-localization of HIV-1 Nef with the AP-2 adaptor protein complex correlates with Nef-induced CD4 down-regulation. EMBO J 1997; 16(23):6964-6976.
35. Munch J, Schindler M, Wildum S, et al. Primary sooty mangabey simian immunodeficiency virus and human immunodeficiency virus Nef Induces Dyslipidemia in Macaques with SIV type 2 nef alleles modulate cell surface expression of various human receptors and enhance viral infectivity and replication. J Virol 2005; 79(16):10547-10560.
36. Schneider J, Luke W, Kirchhoff F, et al. Isolation and characterization of HIV-2ben obtained from a patient with predominantly neurological defects. AIDS 1990; 4(5):455-457.
37. KestlerHWIII, Mori K, Silva DP, et al. Nef genes of SIV. J Med Primatol 1990; 19(3-4):421-429.
38. Jin MJ, Hui H, Robertson DL, et al. Mosaic genome structure of simian immunodeficiency virus from West African green monkeys. EMBO J 1994; 13(12):2935-2947. (Pubitemid 24191704)
39. Kaminchik J, Bashan N, Itach A, Sarver N, Gorecki M, Panet A. Genetic characterization of human immunodeficiency virus type 1 nef gene products translated in vitro and expressed in mammalian cells. J Virol 1991; 65(2):583-588.
40. Mansfield KG, Veazey RS, Hancock A, et al. Induction of disseminated Mycobacterium avium in simian AIDS is dependent upon simian immunodeficiency virus strain and defective granuloma formation. Am J Pathol 2001; 159(2):693-702.
41. Igarashi T, Brown CR, Endo Y, et al. Macrophage are the principal reservoir and sustain high virus loads in rhesus macaques after the depletion of CD4+ T cells by a highly pathogenic simian immunodeficiency virus/HIV type 1 chimera (SHIV): implications for HIV-1 infections of humans. Proc Natl Acad Sci U S A 2001; 98(2):658-663.
42. Swingler S, Mann AM, Zhou J, Swingler C, Stevenson M. Apoptotic killing of HIV-1-infected macrophages is subverted by the viral envelope glycoprotein. PLoS Pathog 2007; 3(9):1281-1290.
43. Stein JH, Klein MA, Bellehumeur JL, et al. Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation 2001; 104(3):257-262.
44. Negredo E, Ribalta J, Paredes R, et al. Reversal of atherogenic lipoprotein profile in HIV-1 infected patients with lipodystrophy after replacing protease inhibitors by nevirapine. AIDS 2002; 16(10):1383-1389.
45. Meynard JL, Lacombe K, Poirier JM, et al. Sustained increase of HDL cholesterol over a 72-week period in HIV-infected patients exposed to an antiretroviral regimen including lopinavir/ritonavir. J Int Assoc Physicians AIDS Care (Chic Ill) 2008; 7(6):311-316.
46. Joven J, Coll B, Tous M, et al. The influence of HIV infection on the correlation between plasma concentrations of monocyte chemoattractant protein-1 and carotid atherosclerosis. Clin Chim Acta 2006; 368(1-2):114-119.
47. Singaraja RR, van Eck M, Bissada N, et al. Both hepatic and extrahepatic ABCA1 have discrete and essential functions in the maintenance of plasma high-density lipoprotein cholesterol levels in vivo. Circulation 2006; 114(12):1301-1309.
48. Prost S, Le DM, Auge S, et al. Human and simian immunodeficiency viruses deregulate early hematopoiesis through a Nef/PPARgamma/ STAT5 signaling pathway in macaques. J Clin Invest 2008; 118(5):1765-1775.
49. Asztalos BF, Schaefer EJ, Horvath KV, et al. Protease inhibitor-based HAART, HDL, and CHD-risk in HIV-infected patients. Atherosclerosis 2006; 184(1):72-77.
50. Balasubramanyam A, Sekhar RV, Jahoor F, Jones PH, Pownall HJ. Pathophysiology of dyslipidemia and increased cardiovascular risk in HIV lipodystrophy: a model of "systemic steatosis." Curr Opin Lipidol 2004; 15(1):59-67.